Sciannameo V, Berchialla P, Avogaro A, et al. - The present study was conducted to explore the transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. The post-stratification approach was implemented based on aggregate data of cardiovascular outcome trials (CVOTs) and individual data of a target population of diabetic outpatients. Researchers applied stratum-specific estimates available from CVOTs to estimate the expected effect size for the target population by weighting the average of the stratum-specific treatment effects according to proportions of a given characteristic in the target population. In comparison with the target population (n = 139,708), the CVOT population (n = 95,816) was younger and had a two to threefold greater prevalence of cardiovascular disease. Based on CVOT stratum-specific effects, it has been reported that cardiovascular protective actions of glucose-lowering medications tested in CVOTs are transferable to a much different real-world population of patients with T2D.